

Clinical trials of Efegatran

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
Efegatran vs heparin			
Klootwijk , 1999 n=432 follow-up: 30 days	Efegatran 0.10.3 mg/kg bolus; 0.1051.200 mg /kg/h infusion for 48h versus UFH 5000 IU bolus; 1000 IU/h infusion	patients with unstable angina	Parallel groups open

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>

References

Klootwijk, 1999:

Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Muller EJ, Poortermans KJ, Deckers JW, Simoons ML Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999 Aug;20:1101-11 [10413640]

Entry terms: efegatran, Me-Phe-Pro-Arg-H, D-methyl-phenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efegatran sulfate,